Asthma Clinical Trial
Official title:
Impact of Adherence to Treatment in Asthma Control Using ASK-20 Questionnaire and Prescription Account.
This survey aims to analyze how adherence to treatment, using Ask-20 questionnaire and prescription count, influences level of asthma control in a sample of patients with severe and moderate-mild asthma.
Duration of illness, poor adherence to treatment, gender, smoking habit, obesity,
concomitant diseases (rhinitis, sinusitis or gastroesophageal reflux) and concomitant
psychiatric disorders may be responsible for an increase and perpetuation of the
inflammatory response as well as a decreased response to treatment and may be easily
identified clinically.
PRIMARY OBJECTIVES: a) analyze how adherence to treatment, using ASK-20 questionnaire and
prescription count, influences level of asthma control in a sample of patients with severe
and moderate-mild asthma.
SECONDARY OBJECTIVES: a) analyze the relation between the level of asthma control according
to the Asthma Control Test (ACT) score and the fraction exhaled of nitric oxide (FeNO); b)
analyze the relation between the level of asthma control according to the ACT score and the
gender. c) analyze the relation between the level of asthma control according to the ACT
score and smoking habit. d) analyze the correlation between the level of asthma control
according to the ACT score and obesity. e) analyze the relation between the level of asthma
control according to the ACT score and concomitant diseases (rhinitis, sinusitis or
gastroesophageal reflux). f) analyze the relation between the level of asthma control
according to the ACT score and concomitant psychiatric disorders. g) analyze the relation
between the level of asthma control according to the ACT score and disease severity under
the terms proposed by Global Initiative for Asthma (GINA).
METHOD: This is a observational cross-sectional study that includes a sample made up of 50
patients with good asthma control and 50 patients with poor asthma control according to the
Asthma Control Test(ACT).
DEVELOPMENT OF THE STUDY After signing the informed consent, data will be collected
including gender, smoking habit, alcohol consumption, environmental and employment factors,
weight, height, body mass index (BMI), history of atopy, disease severity, rhinosinusitis,
gastroesophageal reflux and concomitant psychiatric disorders and a standard physical
examination. Measurement of asthma control with Asthma Control Test (ACT)will be performed.
Then fraction exhaled of nitric oxide (FeNO)measurement and pulmonary function testing
(forced spirometry and bronchodilator test) will be performed .
DEVICES AND MEASUREMENTS: Clinical variables will be collected in a case report form (CRF)
specially developed for the study. Functional study: The spirometry will be performed
according to the recommendations of European Respiratory Society using the Jaeger Master Lab
system.
Bronchodilator test will be performed with albuterol and ipratropium bromide inhalation
solution. FeNO levels will be measured of using the Filt's Vario analyzer which allows for
bronchial or nasal tests, with a flow and volume meter Lilly-type pneumotachograph .
Adherence to treatment will be assessed with the ASK-20 questionnaire and reviewing the
number of prescriptions for asthma during the last 6 months.
;
Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|